Lipocine Q3 2026 net loss narrows 79% to $666,192
LPCN•Lipocine’s third-quarter net loss narrowed 79% year over year to $666,192, while revenue rose to $2.29 million. Cash, cash equivalents and marketable investment securities totaled approximately $28.5 million as of November 4, 2026.
1. Quarterly results
Lipocine’s third-quarter net loss narrowed 79% year over year to $666,192, and revenue rose to $2.29 million, including $2.1 million in license and collaboration revenue. Unrestricted cash, cash equivalents and marketable investment securities totaled approximately $28.5 million as of November 4, 2026.
2. BLOOM study
The Phase 3 BLOOM study for postpartum depression began in September and is targeting approximately 120 participants to support a potential NDA submission.
